FibroGen (FGEN) – Research Analysts’ Recent Ratings Changes

FibroGen (NASDAQ: FGEN) recently received a number of ratings updates from brokerages and research firms:

• 4/1/2025 – FibroGen had its “market perform” rating reaffirmed by analysts at William Blair.
• 3/30/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/22/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/18/2025 – FibroGen had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 3/14/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/6/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/21/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/20/2025 – FibroGen had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 2/13/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/5/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

FibroGen Price Performance

Shares of FGEN stock opened at $0.31 on Thursday. The business has a fifty day moving average of $0.45 and a 200 day moving average of $0.43. FibroGen, Inc. has a 1 year low of $0.18 and a 1 year high of $2.15. The firm has a market capitalization of $30.90 million, a price-to-earnings ratio of -0.25 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). The business had revenue of $3.14 million for the quarter, compared to analyst estimates of $24.91 million. As a group, equities research analysts expect that FibroGen, Inc. will post -0.8 earnings per share for the current year.

Insider Buying and Selling

In other FibroGen news, Director James A. Schoeneck purchased 250,000 shares of FibroGen stock in a transaction that occurred on Thursday, March 20th. The stock was bought at an average price of $0.35 per share, with a total value of $87,500.00. Following the acquisition, the director now owns 323,722 shares of the company’s stock, valued at $113,302.70. This trade represents a 339.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Thane Wettig acquired 145,000 shares of the company’s stock in a transaction on Monday, March 24th. The stock was acquired at an average cost of $0.35 per share, for a total transaction of $50,750.00. Following the completion of the acquisition, the chief executive officer now owns 543,329 shares of the company’s stock, valued at $190,165.15. This trade represents a 36.40 % increase in their position. The disclosure for this purchase can be found here. 1.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its stake in FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after buying an additional 1,358,194 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of FibroGen by 80.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 605,572 shares in the last quarter. Geode Capital Management LLC lifted its holdings in FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 32,884 shares in the last quarter. Two Sigma Advisers LP boosted its stake in FibroGen by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after purchasing an additional 135,600 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of FibroGen by 19.6% during the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 98,888 shares in the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.